| Keyword search (4,163 papers available) | ![]() |
"Su C" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Correlations of pilot trainees brainwave dynamics with subjective performance evaluations: insights from EEG microstate analysis | Zhao M; Law A; Su C; Jennings S; Bourgon A; Jia W; Larose MH; Bowness D; Zeng Y; | 40109507 ENCS |
| 2 | Monitoring pilot trainees' cognitive control under a simulator-based training process with EEG microstate analysis | Zhao M; Jia W; Jennings S; Law A; Bourgon A; Su C; Larose MH; Grenier H; Bowness D; Zeng Y; | 39428425 ENCS |
| 3 | A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease | Hankins JS; Brambilla D; Potter MB; Kutlar A; Gibson RW; King AA; Baumann AA; Melvin CL; Gordeuk VR; Hsu LL; Nwosu C; Porter JS; Alberts NM; Badawy SM; Simon J; Glassberg J; Lottenberg R; DiMartino L; Jacobs S; Fernandez ME; Bosworth H; Klesges LM; Shah N; | 37738155 CONCORDIA |
| 4 | Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators | Pizzo A; Porter JS; Carroll Y; Burcheri A; Smeltzer MP; Beestrum M; Nwosu C; Badawy SM; Hankins JS; Klesges LM; Alberts NM; | 37691131 PSYCHOLOGY |
| Title: | Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators | ||||
| Authors: | Pizzo A, Porter JS, Carroll Y, Burcheri A, Smeltzer MP, Beestrum M, Nwosu C, Badawy SM, Hankins JS, Klesges LM, Alberts NM | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/37691131/ | ||||
| DOI: | 10.1111/bjh.19099 | ||||
| Publication: | British journal of haematology | ||||
| Keywords: | adherence; hydroxycarbamide; sickle cell anaemia; | ||||
| PMID: | 37691131 | Category: | Date Added: | 2023-09-11 | |
| Dept Affiliation: | PSYCHOLOGY | ||||
Description: |
Sickle cell disease (SCD) is an inherited red blood cell disorder associated with frequent painful events and organ damage. Hydroxyurea (HU) is the recommended evidence-based treatment of SCD. However, among patients eligible for HU, prescription rates are low. Utilizing a scoping review approach, we summarized and synthesized relevant findings regarding provider barriers and facilitators to the prescription of HU in youth and adults with SCD and provided suggestions for future implementation strategies to improve prescription rates. Relevant databases were searched using specified search terms. Articles reporting provider barriers and/or facilitators to prescribing HU were included. A total of 10 studies met the inclusion criteria. Common barriers to the prescription of HU identified by providers included: doubts around patients' adherence to HU and their engaging in required testing, concerns about side effects, lack of knowledge, cost and patient concerns about side effects. Facilitators to the prescription of HU included beliefs in the effectiveness of HU, provider demographics and knowledge. Findings suggest significant provider biases exist, particularly in the form of negative perceptions towards patients' ability to adhere to taking HU and engaging in the required follow-up. Improving provider knowledge and attitudes towards HU and SCD may help improve low prescription rates. |



